Clinical Phase II of SOM0226 for transthyretin amyloidosis

posted on April 17, 2014

SOM Biotech and The Vall d’Hebron Institute of Research (VHIR) have signed an agreement to jointly develop the clinical Phase II of SOM0226 drug for transthyretin Amyloidosis (ATTR).